CELL REGULATORY SIALOPROTEIN

细胞调节唾液酸蛋白

• 批准号: 3493330
• 负责人: FLOYD E TAUB
• 金额: $ 5万
• 依托单位: SYNCHROCELL, INC.
• 依托单位国家: 美国
• 财政年份: 1993
• 资助国家: 美国
• 起止时间: 1993-03-01 至 1994-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3493330
• 关键词: antineoplastics; biomaterial development /preparation; cell differentiation; cell growth regulation; drug screening /evaluation; glycoproteins; growth inhibitors; sialate; tissue /cell culture

CeReS (Cell Regulatory Sialoprotein) is a molecule demonstrated to: 1. Inhibit primary, continuous and transformed cell lines, 2. Affect cells from species as diverse as insects and humans, 3. Cause one cell line to terminally differentiate, 4. Reversibly inhibit other lines (90%-98% of the cells recover), 5. Specifically arrest cells near the Gl/S interface, 6. Synchronously release cells to enter S phase and then mitosis (synchronization remains through at least one additional cell cycle). CeReS is distinct from all known drugs and cell surface components functionally and according to the limited peptide sequence and preliminary DNA sequence data available. The aims of this study are to determine the feasibility of using CeReS to improve and increase efficiency of cell culture, to provide new models for differentiation; and to test a wide variety of cancer cell lines for sensitivity or resistance to CeReS. Preliminary data indicates differential sensitivity of cells suggesting potential therapeutic uses. SynchroCell, the exclusive licensee of CeReS, believes this and related molecules will be important products for the research community, significantly aiding in understanding regulation and carcinogenesis and as a cell culture tool of commercial importance. Improved cancer therapies are potential applications of CeReS and of the knowledge gained with the aid of CeReS.

CERES（细胞调节性唾液蛋白）是一种分子，显示为：1。 抑制原发性，连续和转化的细胞系2。影响细胞 从像昆虫和人类一样多样化的物种，3。导致一个细胞系 最终区分，4。可逆地抑制其他线（90％-98％ 细胞恢复），5。特别是在GL/S界面附近捕捉细胞， 6。同步释放细胞进入S相，然后释放有丝分裂 （同步保持至少一个额外的单元周期）。 CERES与所有已知药物和细胞表面成分不同 在功能上，根据有限的肽序列和 可用的初步DNA序列数据。 这项研究的目的是确定使用CERES的可行性 提高和提高细胞培养的效率，提供新的模型 差异化；并测试各种癌细胞系的 敏感性或对CERES的抵抗力。 初步数据指示 细胞的差异敏感性表明潜在的治疗用途。 CERES的独家许可人Synchrocell认为这与相关 分子将是研究界的重要产品， 显着帮助理解调节和癌变以及 作为商业重要性的细胞培养工具。 改善癌症 疗法是谷神星的潜在应用和所获得的知识 借助谷神庙。